| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
14,323 |
9,292 |
$290K |
| 80053 |
Comprehensive metabolic panel |
48,389 |
34,073 |
$247K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
60,290 |
39,146 |
$183K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
5,258 |
4,066 |
$180K |
| 84443 |
Thyroid stimulating hormone (TSH) |
8,736 |
7,312 |
$73K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
8,459 |
4,147 |
$72K |
| 84484 |
|
12,532 |
9,548 |
$56K |
| 83735 |
|
16,157 |
10,966 |
$56K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,986 |
1,822 |
$53K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
11,067 |
6,152 |
$47K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
5,329 |
4,225 |
$47K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
2,952 |
2,768 |
$45K |
| 83880 |
|
4,181 |
3,212 |
$44K |
| 83690 |
|
11,467 |
9,572 |
$40K |
| 83605 |
|
7,837 |
6,163 |
$40K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,585 |
1,541 |
$34K |
| 81025 |
|
11,817 |
10,113 |
$25K |
| 81001 |
|
17,255 |
14,819 |
$25K |
| 82805 |
|
900 |
587 |
$23K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
336 |
263 |
$20K |
| 85610 |
|
8,897 |
6,287 |
$18K |
| 84702 |
|
3,159 |
2,465 |
$16K |
| 85379 |
|
3,681 |
3,277 |
$14K |
| 85730 |
|
4,489 |
3,800 |
$14K |
| 84703 |
|
3,822 |
3,442 |
$13K |
| 87807 |
|
1,952 |
1,448 |
$12K |
| 88342 |
|
459 |
410 |
$10K |
| 86140 |
|
4,233 |
3,733 |
$10K |
| 82550 |
|
3,316 |
2,503 |
$10K |
| 82150 |
|
2,549 |
2,171 |
$9K |
| 81003 |
|
7,246 |
6,529 |
$8K |
| 84100 |
|
3,091 |
1,520 |
$7K |
| 88307 |
|
112 |
89 |
$6K |
| 87210 |
|
2,237 |
2,071 |
$6K |
| 82140 |
|
1,281 |
867 |
$5K |
| 85027 |
|
1,729 |
1,404 |
$5K |
| 84550 |
|
2,081 |
1,046 |
$4K |
| 85652 |
|
2,430 |
2,216 |
$3K |
| 80076 |
|
611 |
484 |
$2K |
| 83615 |
|
702 |
604 |
$2K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
49 |
49 |
$2K |
| 85060 |
|
118 |
99 |
$1K |
| 88304 |
|
57 |
53 |
$1K |
| 84145 |
|
99 |
90 |
$1K |
| 85014 |
|
924 |
872 |
$1K |
| 85018 |
|
918 |
874 |
$1K |
| 87040 |
|
72 |
69 |
$846.18 |
| 82077 |
|
79 |
69 |
$818.44 |
| 82009 |
|
522 |
407 |
$657.95 |
| 80202 |
|
93 |
49 |
$657.36 |
| 82570 |
|
235 |
200 |
$558.26 |
| 82950 |
|
194 |
190 |
$533.57 |
| 86901 |
|
79 |
73 |
$182.88 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
33 |
32 |
$181.50 |
| 85045 |
|
155 |
134 |
$179.47 |
| 82272 |
|
156 |
146 |
$178.82 |
| 84439 |
|
41 |
39 |
$158.64 |
| 86780 |
|
16 |
16 |
$138.24 |
| 86850 |
|
50 |
47 |
$137.78 |
| 84300 |
|
55 |
44 |
$118.72 |
| 86900 |
|
64 |
58 |
$109.95 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
34 |
34 |
$103.50 |
| 84156 |
|
61 |
53 |
$71.71 |
| 83550 |
|
15 |
15 |
$63.56 |
| 80061 |
Lipid panel |
39 |
38 |
$53.40 |
| 83540 |
|
16 |
16 |
$50.76 |
| 85651 |
|
40 |
34 |
$34.50 |
| 86592 |
|
12 |
12 |
$23.90 |
| 36415 |
Collection of venous blood by venipuncture |
246 |
214 |
$4.10 |